Outcomes were assessed according to the Female Sexual Function Index (FSFI) and the revised Female Sexual Distress Scale (FSDS-R). FSFI records arousal, desire, pain, orgasm, satisfaction, and lubrication while the FSDS-R measures sexual distress in women. Patient reported FSFI and FSDS-R scores were recorded at the time of injection and again at the 12-16 week follow up.
Of the 11 women 7 started with elevated levels of sexual distressed as measured by an FSDS-R score of 11 or more. At follow up, 5 of the 7 distressed women decreased their FSDS-R scores to less than 11. Contrarily, 2 women reported increased sexual distress; one because of hyper arousal and the other from the loss of a relationship.¹